Patients keep asking why their wrinkle relaxer fades so fast. At a May conference, Ipsens investigational neurotoxin corabotase posted its strongest Phase 2 data yet, aimed squarely at that durability gap.
At the SCALE 2026 conference in May, Ipsens investigational neurotoxin corabotase delivered its strongest Phase 2 data yet. In the LANTIC trial, 60.8 percent of patients on the 50ng dose maintained none or mild frown-line severity at week 24, versus 36.7 percent for Dysport, with average onset under one day. The 50ng dose advanced to Phase 3. It is not FDA-approved.
The neurotoxin market has been stable for years, but a wave of next-generation candidates is now chasing one goal: longer-lasting results.
May brought the strongest data yet for one of those contenders.
At the SCALE 2026 conference in Nashville, Ipsen presented Phase 2 LANTIC data on corabotase, an investigational neurotoxin. Among patients treated with the 50ng dose, 60.8 percent maintained none or mild glabellar (frown) line severity at week 24, compared with 36.7 percent in the Dysport comparison arm. Onset averaged about 0.84 days, and 82.8 percent of patients reported being satisfied or very satisfied at week 24. The 50ng dose was selected to advance into the Phase 3 LAURITE program.
The headline appeal is duration: a toxin engineered to hold results closer to six months would address a common patient frustration that standard toxins fade in three to four months. Crucially, corabotase is not FDA-approved and has no announced U.S. commercial timeline, so nothing changes on provider menus today; the data is investigational and forward-looking.
For consumers, corabotase is a preview of where neurotoxins may be heading, not an option to request now. If durability matters to you, this is the gap the product is designed to close, but Phase 2 results in a studied population are not guarantees, and a Phase 3 program and FDA review still lie ahead. The practical takeaway is to set realistic expectations with current, approved toxins and treat pipeline news as context.
Watch the Phase 3 LAURITE results and any eventual FDA submission, which would determine whether and when corabotase reaches U.S. patients. Also watch how durability claims hold up in larger, longer studies and against established toxins. Until approval, corabotase remains investigational, and U.S. availability depends on regulatory action rather than conference enthusiasm.